Anticipatory immune suppression and nausea in women receiving cyclic chemotherapy for ovarian cancer.
Nausea and immune function were assessed in 20 cancer patients in the hospital prior to chemotherapy and compared with assessments conducted at home. Proliferative responses to T-cell mitogens were lower for cells isolated from hospital blood samples than for home samples obtained several days earlier. Patients also experienced increased nausea in the hospital. Hierarchical multiple regression analyses indicated that decreased immune function in the hospital was not related to increased anxiety. The observed anticipatory immune suppression is consistent with the hypothesis that chemotherapy patients may develop conditioned immune suppression as well as conditioned nausea after repeated pairings of hospital stimuli with the emetic and immunosuppressive effects of chemotherapy.
Bovbjerg
D H
DH
Cornell University Medical College, New York, New York.
Redd
W H
WH
Maier
L A
LA
Holland
J C
JC
Lesko
L M
LM
Niedzwiecki
D
D
Rubin
S C
SC
Hakes
T B
TB
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D002945:Cisplatin / Q000009:adverse effects; D003520:Cyclophosphamide / Q000009:adverse effects; D004317:Doxorubicin / Q000009:adverse effects; D005260:Female; D006801:Humans; D007108:Immune Tolerance / Q000187:drug effects*; D007958:Leukocyte Count / Q000187:drug effects; D008213:Lymphocyte Activation / Q000187:drug effects; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D014840:Vomiting, Anticipatory / Q000276:immunology*
D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin